Diabetes: how to manage cardiovascular risk in secondary prevention patients
Atherosclerotic cardiovascular disease (ASCVD) commonly affects people with type 2 diabetes (T2D). Historically, traditional cardiovascular (CV) risk-lowering therapies in patients with T2D and ASCVD have included antiplatelet agents, blood pressure-lowering therapies, lipid-lowering therapies and h...
Saved in:
Main Authors: | Sarah L Anderson (Author), Joel C Marrs (Author) |
---|---|
Format: | Book |
Published: |
BioExcel Publishing Ltd,
2022-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Tirzepatide for type 2 diabetes
by: Sarah L Anderson, et al.
Published: (2023) -
Ertugliflozin in the treatment of type 2 diabetes mellitus
by: Joel C Marrs, et al.
Published: (2020) -
Bempedoic acid for the treatment of dyslipidemia
by: Joel C Marrs, et al.
Published: (2020) -
Sacubitril/valsartan: evaluation of safety and efficacy as an antihypertensive treatment
by: Sarah L Anderson, et al.
Published: (2018) -
Inclisiran for the treatment of hypercholesterolaemia
by: Joel C Marrs, et al.
Published: (2024)